Electromed (ELMD) possesses solid growth attributes, which could help it handily outperform the market.
The consensus price target hints at a 37% upside potential for Electromed (ELMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ROKU, NRIM and ELMD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 17, 2025.
| Health Care Equipment & Supplies Industry | Healthcare Sector | James L. Cunniff CEO | AMEX Exchange | 285409108 CUSIP |
| US Country | 174 Employees | - Last Dividend | - Last Split | 13 Aug 2010 IPO Date |
Electromed, Inc. is a pioneering company focusing on the advancement, manufacturing, marketing, and sales of airway clearance therapy alongside related products leveraging high frequency chest wall oscillation (HFCWO) therapy. This innovative approach is pivotal in pulmonary care for patients across various age groups both within the United States and internationally. With a foundation laid in 1992 and headquartered in New Prague, Minnesota, Electromed, Inc. is dedicated to enhancing the quality of life for individuals suffering from compromised pulmonary function due to conditions such as bronchiectasis, cystic fibrosis, and neuromuscular diseases. The company primarily serves the home health care and institutional markets, reaching its customers through physicians, health care providers, and direct patient sales.
This is a flagship product designed by Electromed, Inc., providing an effective airway clearance therapy through the application of high frequency chest wall oscillation. The system is engineered for ease of use and comfort, addressing the needs of patients with compromised pulmonary functions.
This system encompasses an inflatable therapy garment, a programmable air pulse generator, and a patented single hose. This hose functions to deliver air pulses from the generator to the garment, facilitating effective delivery of airway clearance therapy to the patient.
Integrating wireless technology, SmartVest Connect offers a personalized HFCWO therapy management portal. This innovation supports improved monitoring and management of therapy, empowering patients with chronic pulmonary conditions to engage more actively in their treatment plans.
Specifically designed for the acute care setting, these products cater to health care providers offering a solution for effective airway clearance on a single-patient basis. They are intended to meet the urgent needs of patients in healthcare facilities.